BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 18182242)

  • 1. Structural modification of the highly potent peptide bradykinin B1 receptor antagonist B9958.
    Gera L; Stewart JM; Fortin JP; Morissette G; Marceau F
    Int Immunopharmacol; 2008 Feb; 8(2):289-92. PubMed ID: 18182242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and in vivo evaluation of metabolically resistant antagonists of B1 receptors for kinins.
    Drapeau G; Audet R; Levesque L; Godin D; Marceau F
    J Pharmacol Exp Ther; 1993 Jul; 266(1):192-9. PubMed ID: 8392550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel nonpeptide antagonist of the kinin B1 receptor: effects at the rabbit receptor.
    Morissette G; Fortin JP; Otis S; Bouthillier J; Marceau F
    J Pharmacol Exp Ther; 2004 Dec; 311(3):1121-30. PubMed ID: 15277582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endogenous aminopeptidase N decreases the potency of peptide agonists and antagonists of the kinin B1 receptors in the rabbit aorta.
    Fortin JP; Gera L; Bouthillier J; Stewart JM; Adam A; Marceau F
    J Pharmacol Exp Ther; 2005 Sep; 314(3):1169-76. PubMed ID: 15919764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a dual-function peptide that combines aminopeptidase N inhibition and kinin B1 receptor antagonism.
    Gera L; Fortin JP; Adam A; Stewart JM; Marceau F
    J Pharmacol Exp Ther; 2006 Apr; 317(1):300-8. PubMed ID: 16368899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Partial agonists and full antagonists at the human and murine bradykinin B1 receptors.
    MacNeil T; Feighner S; Hreniuk DL; Hess JF; Van der Ploeg LH
    Can J Physiol Pharmacol; 1997 Jun; 75(6):735-40. PubMed ID: 9276157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of secondary structures of bradykinin B1 receptor antagonists with their activity.
    Miskolzie M; Gera L; Stewart JM; Kotovych G
    J Biomol Struct Dyn; 2002 Feb; 19(4):585-93. PubMed ID: 11843620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative studies of three 68Ga-labeled [Des-Arg10]kallidin derivatives for imaging bradykinin B1 receptor expression with PET.
    Lin KS; Amouroux G; Pan J; Zhang Z; Jenni S; Lau J; Liu Z; Hundal-Jabal N; Colpo N; Bénard F
    J Nucl Med; 2015 Apr; 56(4):622-7. PubMed ID: 25745086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiolabeled B9958 Derivatives for Imaging Bradykinin B1 Receptor Expression with Positron Emission Tomography: Effect of the Radiolabel-Chelator Complex on Biodistribution and Tumor Uptake.
    Zhang Z; Amouroux G; Pan J; Jenni S; Zeisler J; Zhang C; Liu Z; Perrin DM; Bénard F; Lin KS
    Mol Pharm; 2016 Aug; 13(8):2823-32. PubMed ID: 27348517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A fluorescent version of the bradykinin B2 receptor antagonist B-9430: pharmacological characterization and use in live cell imaging.
    Bawolak MT; Gera L; Bouthillier J; Stewart JM; Adam A; Marceau F
    Peptides; 2008 Sep; 29(9):1626-30. PubMed ID: 18565624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (18)F-trifluoroborate derivatives of [des-arg(10)]kallidin for imaging bradykinin b1 receptor expression with positron emission tomography.
    Liu Z; Amouroux G; Zhang Z; Pan J; Hundal-Jabal N; Colpo N; Lau J; Perrin DM; Bénard F; Lin KS
    Mol Pharm; 2015 Mar; 12(3):974-82. PubMed ID: 25629412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination cancer chemotherapy with one compound: pluripotent bradykinin antagonists.
    Stewart JM; Gera L; Chan DC; York EJ; Simkeviciene V; Bunn PA; Taraseviciene-Stewart L
    Peptides; 2005 Aug; 26(8):1288-91. PubMed ID: 15878795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bradykinin receptor antagonists containing N-substituted amino acids: in vitro and in vivo B(2) and B(1) receptor antagonist activity.
    Goodfellow VS; Marathe MV; Kuhlman KG; Fitzpatrick TD; Cuadrado D; Hanson W; Zuzack JS; Ross SE; Wieczorek M; Burkard M; Whalley ET
    J Med Chem; 1996 Mar; 39(7):1472-84. PubMed ID: 8691478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of human and rabbit arterial smooth muscle cell migration mediated by the kinin B1 receptor: role of receptor density and released mediators.
    Morissette G; Sabourin T; Adam A; Marceau F
    Can J Physiol Pharmacol; 2006 Nov; 84(11):1107-19. PubMed ID: 17218975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual antagonists of the bradykinin B1 and B2 receptors based on a postulated common pharmacophore from existing non-peptide antagonists.
    Morissette G; Bouthillier J; Marceau F
    Biol Chem; 2006 Feb; 387(2):189-94. PubMed ID: 16497151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-affinity binding of peptide agonists to the human B1 bradykinin receptor depends on interaction between the peptide N-terminal L-lysine and the fourth extracellular domain of the receptor.
    Fathy DB; Kyle DJ; Leeb-Lundberg LM
    Mol Pharmacol; 2000 Jan; 57(1):171-9. PubMed ID: 10617692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-1beta enhances the action of bradykinin in rat myenteric neurons through up-regulation of glial B1 receptor expression.
    Murakami M; Ohta T; Ito S
    Neuroscience; 2008 Jan; 151(1):222-31. PubMed ID: 18053651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Both B1R and B2R act as intermediate signaling molecules in high glucose-induced stimulation of glutamate uptake in ARPE cells.
    Lim SK; Han HJ; Kim KY; Park SH
    J Cell Physiol; 2009 Dec; 221(3):677-87. PubMed ID: 19725054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological characterization and radioligand binding properties of a high-affinity, nonpeptide, bradykinin B1 receptor antagonist.
    Ransom RW; Harrell CM; Reiss DR; Murphy KL; Chang RS; Hess JF; Miller PJ; O'Malley SS; Hey PJ; Kunapuli P; Su DS; Markowitz MK; Wallace MA; Raab CE; Jones AN; Dean DC; Pettibone DJ; Freidinger RM; Bock MG
    Eur J Pharmacol; 2004 Sep; 499(1-2):77-84. PubMed ID: 15363953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B-9972 (D-Arg-[Hyp3,Igl5,Oic7,Igl8]-bradykinin) is an inactivation-resistant agonist of the bradykinin B2 receptor derived from the peptide antagonist B-9430 (D-Arg-[Hyp3,Igl5,D-Igl7,Oic8]-bradykinin): pharmacologic profile and effective induction of receptor degradation.
    Bawolak MT; Gera L; Morissette G; Stewart JM; Marceau F
    J Pharmacol Exp Ther; 2007 Nov; 323(2):534-46. PubMed ID: 17699739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.